Individual generic drug information

silver sulfadiazine

Reference monograph

Part of registered formulation

SILVER SULFADIAZINE

Reference record: Silver sulfadiazine
Source: BNF 80 (2020–2021)
Printed source pages: 1319
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Silver sulfadiazine only.

Indications And Dose

Prophylaxis and treatment of infection in burn wounds ▶TO THE SKIN ▶Child: Apply daily, may be applied more frequently if very exudative ▶Adult: Apply daily, may be applied more frequently if very exudative For conservative management of finger-tip injuries ▶TO THE SKIN ▶Child: Apply every 2–3 days, consult product literature for details ▶Adult: Apply every 2–3 days, consult product literature for details Adjunct to prophylaxis of infection in skin graft donor sites and extensive abrasions ▶TO THE SKIN ▶Adult: (consult product literature) Adjunct to short-term treatment of infection in pressure sores ▶TO THE SKIN ▶Adult: Apply once daily or on alternate days As an adjunct to short-term treatment of infection in leg ulcers ▶TO THE SKIN ▶Adult: Apply once daily or on alternate days, not recommended if ulcer is very exudative l UNLICENSED USE ▶In children No age range speciﬁed by manufacturer.

Source page 1319

Contra Indications

Not recommended for neonates

Source page 1319

Cautions

G6PD deﬁciency CAUTIONS, FURTHER INFORMATION ▶Large areas Plasma-sulfadiazine concentrations may approach therapeutic levels with side-effects and interactions as for sulfonamides if large areas of skin are treated.

Source page 1319

Allergy And Cross Sensitivity

Contra-indicated in patients with sensitivity to sulfonamides.

Source page 1319

Safety

Extracted information for Silver sulfadiazine only.

Interactions

→Appendix 1: silver sulfadiazine

Source page 1319

Side Effects

▶Common or very common Leucopenia. skin reactions ▶Rare or very rare Argyria (following treatment of large areas of skin or long term use). renal failure SIDE-EFFECTS, FURTHER INFORMATION Leucopenia developing 2–3 days after starting treatment of burns patients is reported usually to be self-limiting and silver sulfadiazine need not usually be discontinued provided blood counts are monitored carefully to ensure return to normality within a few days.

Source page 1319

Pregnancy

Risk of neonatal haemolysis and methaemoglobinaemia in third trimester.

Source page 1319

Breast Feeding

Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deﬁcient infants.

Source page 1319

Hepatic Impairment

Manufacturer advises caution in signiﬁcant hepatic impairment.

Source page 1319

Renal Impairment

Manufacturer advises caution if signiﬁcant impairment.

Source page 1319

Monitoring Requirements

Monitor for leucopenia.

Source page 1319

Dose and formulations

Extracted information for Silver sulfadiazine only.

Directions For Administration

Apply with sterile applicator.

Source page 1319

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Cream EXCIPIENTS: May contain Cetostearyl alcohol (including cetyl and stearyl alcohol), polysorbates, propylene glycol ▶Flamazine (Smith & Nephew Healthcare Ltd) Sulfadiazine silver 10 mg per 1 gram Flamazine 1% cream | 20 gram P £2.91 | 50 gram P £3.85 DT = £3.85 | 250 gram P £10.32 DT = £10.32 | 500 gram P £18.27 DT = £18.27 ANTIBACTERIALS › OTHER

Source page 1319

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

Apply daily, may be applied more frequently if

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

Apply every 2–3 days, consult product literature

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

(consult product literature)

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

Apply once daily or on alternate days

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

Apply once daily or on alternate days, not

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.

Individual generic drug information

silver sulfadiazine

Reference monograph

Part of registered formulation

SILVER SULFADIAZINE

Reference record: Silver sulfadiazine
Source: BNF 80 (2020–2021)
Printed source pages: 1319
Age groups indexed: 2

Individual active ingredientSource records are displayed separately

Some source sections could not be separated reliably in the extraction. Review the printed source pages when a field is missing or incomplete.

Overview

Extracted information for Silver sulfadiazine only.

Indications And Dose

Source page 1319

Contra Indications

Not recommended for neonates

Source page 1319

Cautions

Source page 1319

Allergy And Cross Sensitivity

Contra-indicated in patients with sensitivity to sulfonamides.

Source page 1319

Safety

Extracted information for Silver sulfadiazine only.

Interactions

→Appendix 1: silver sulfadiazine

Source page 1319

Side Effects

Source page 1319

Pregnancy

Risk of neonatal haemolysis and methaemoglobinaemia in third trimester.

Source page 1319

Breast Feeding

Small risk of kernicterus in jaundiced infants and of haemolysis in G6PD-deﬁcient infants.

Source page 1319

Hepatic Impairment

Manufacturer advises caution in signiﬁcant hepatic impairment.

Source page 1319

Renal Impairment

Manufacturer advises caution if signiﬁcant impairment.

Source page 1319

Monitoring Requirements

Monitor for leucopenia.

Source page 1319

Dose and formulations

Extracted information for Silver sulfadiazine only.

Directions For Administration

Apply with sterile applicator.

Source page 1319

Medicinal Forms

Source page 1319

Dose text by age group

Filter the extracted dose blocks for this individual drug.

Adults

First line only; read the complete Indications and dose section above.

Apply daily, may be applied more frequently if

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

Apply every 2–3 days, consult product literature

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

(consult product literature)

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

Apply once daily or on alternate days

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Adults

First line only; read the complete Indications and dose section above.

Apply once daily or on alternate days, not

This is a first-line fragment. Read the full Indications and Dose section above.

Candidate age grouping · source page 1319

Age labels are extracted from the printed dose headings and require clinical review. Confirm current local guidance, dose, route, formulation, contraindications and interactions before prescribing.